Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Phase I, Open-Label, Non-Randomized Clinical Trial to Evaluate the Safety and Preliminary Efficacy of Adipose-Derived Mesenchymal Stem Cell Secretome Capsules (VinVital) in Patients With Frailty Syndrome

Authors not listed

Vinmec Research Institute of Stem Cell and Gene Technology · 2026

Stem-cell exhaustion Altered intercellular communication Stem-cell therapy Human Randomized controlled trial

Abstract

This is a Phase I, open-label, non-randomized clinical trial to evaluate the safety and preliminary efficacy of adipose-derived mesenchymal stem cell secretome capsules (VinVital) in patients with frailty syndrome. A total of 20 participants aged 60 to 75 will receive oral VinVital for 3 months, with an additional 3-month follow-up period (total 6 months). The primary objective is to assess safety based on the frequency and severity of adverse events (AEs) and serious adverse events (SAEs) according to CTCAE v5.0.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-10-15 MST

Cite this

APA

Anonymous. (2026). A Phase I, Open-Label, Non-Randomized Clinical Trial to Evaluate the Safety and Preliminary Efficacy of Adipose-Derived Mesenchymal Stem Cell Secretome Capsules (VinVital) in Patients With Frailty Syndrome. <em>Vinmec Research Institute of Stem Cell and Gene Technology</em>. https://clinicaltrials.gov/study/NCT07856602

Vancouver

Anonymous. A Phase I, Open-Label, Non-Randomized Clinical Trial to Evaluate the Safety and Preliminary Efficacy of Adipose-Derived Mesenchymal Stem Cell Secretome Capsules (VinVital) in Patients With Frailty Syndrome. Vinmec Research Institute of Stem Cell and Gene Technology. 2026.

BibTeX

@misc{anon2026APhase, title = {A Phase I, Open-Label, Non-Randomized Clinical Trial to Evaluate the Safety and Preliminary Efficacy of Adipose-Derived Mesenchymal Stem Cell Secretome Capsules (VinVital) in Patients With Frailty Syndrome}, author = {Anonymous}, journal = {Vinmec Research Institute of Stem Cell and Gene Technology}, year = {2026}, }